Tag: Apellis
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LO… – Press...
NEW ORLEANS, Aug. 11, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Inves… –...
WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of...
Apellis Presents Phase 3 Functional Analyses of SYFOVRE (pegcetacoplan injectio… –...
Showed visual function and quality-of-life benefits in patients with extrafoveal lesionsSlowed the loss of retinal pigmented epithelial and photoreceptor cells, both of which...
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™...
EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching...
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European...
Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with...
Apellis to Showcase Leadership in Retina at Association for Research in...
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted...